Synergistic Risks of Lymphoid Malignancies in MBL and CHIP

In this episode of the VJHemOnc podcast, we explore clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) – conditions increasingly recognized as early indicators of myelodysplastic syndromes and acute myeloid leukemia.

Joining the discussion are leading experts George Vassiliou, MBBS, PhD, The University of Cambridge, Cambridge, UK, Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Mrinal Patnaik, MBBS, Mayo Clinic, Rochester, MN, Susan Slager, PhD, Mayo Clinic, Rochester, MN, and Anton Langerak, PhD, Erasmus MC, Rotterdam, The Netherlands. Together, they delve into recent advances in our understanding of CHIP and CCUS, touch on monoclonal B-cell lymphocytosis as another precursor condition, and share their insights on the potential value of early intervention in these pre-malignant states.

The post CHIP & CCUS: advances in understanding and should we treat these precursor conditions? appeared first on VJHemOnc.